Invesaro

Stocks Health care NUS

NYSE · Health care

NU Skin Enterprises, Inc. (NUS)

NU Skin Enterprises, Inc. brought in $1.4B of revenue over the twelve months to June 30, 2026, down 15.4% from a year earlier. It posted a net loss of $216.4M. Operating cash flow minus capital spending left $46M of free cash flow in fiscal 2025. At June 30, 2026 it held $189.6M in cash against $213.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

Price
$4.63
+0.22% on the day · September 25, 2026
52-week range $4.49 to $12.50
Market cap
$225.4M
Revenue (last 12 months)
$1.4B
-15.4% year on year
Net margin
-15.7%
P/E
1.5
on FY2025 diluted EPS

What NU Skin Enterprises, Inc. does

NU Skin Enterprises, Inc. is registered with the SEC under industry code SIC 5122 (Wholesale-Drugs, Proprietaries & Druggists' Sundries). Its shares trade on NYSE under the ticker NUS.

Revenue and profit by year

Revenue
FY18: $2.7B $2.7B FY18FY19: $2.4B $2.4B FY19FY20: $2.6B $2.6B FY20FY21: $2.7B $2.7B FY21FY22: $2.2B $2.2B FY22FY23: $2B $2B FY23FY24: $1.7B $1.7B FY24FY25: $1.5B $1.5B FY25
Net income
FY18: $121.9M $121.9M FY18FY19: $173.6M $173.6M FY19FY20: $191.4M $191.4M FY20FY21: $147.3M $147.3M FY21FY22: $104.8M $104.8M FY22FY23: $8.6M $8.6M FY23FY24: -$146.6M -$146.6M FY24FY25: $160.2M $160.2M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$1.5B$65.8M$160.2M$3.18$46M
2024$1.7B-$151.6M-$146.6M-$2.95$70.2M
2023$2B$48.3M$8.6M$0.17$60.1M
2022$2.2B$110.8M$104.8M$2.07$49M
2021$2.7B$234M$147.3M$2.86$73M
2020$2.6B$257.6M$191.4M$3.63$315.3M
Next report expected around November 5, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 6, 2025. Not a date the company has announced. See the report calendar

Where NUS ranks in Health care

Revenue$1.5B
#122 of 523 in Health care · Top 23%
Revenue growth-14.3%
#395 of 437 in Health care · Bottom 10%
Net margin10.8%
#91 of 447 in Health care · Top 20%
Free cash flow margin3.1%
#181 of 408 in Health care · Top 44%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out $11.8M in cash dividends, 7% of its net income.

Fiscal yearPer sharePaid outOf profit
2025n/a$11.8M7%
2024n/a$11.9Mn/a
2023n/a$77.6M903%
2022n/a$77M74%
2021n/a$76.3M52%
2020n/a$78.4M41%

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What NU Skin Enterprises, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 21, 2026
  2. August 10, 2026
    Quarterly report 10-Q · period to June 30, 2026
  3. August 10, 2026
  4. June 1, 2026
  5. May 29, 2026
  6. May 21, 2026
  7. May 14, 2026
  8. May 8, 2026
  9. May 8, 2026
    Quarterly report 10-Q · period to March 31, 2026
  10. May 7, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 10, 2026. Insider transactions on SEC

What is NUS worth? A DCF from its reported cash flow

Insider trades

What the people running NU Skin Enterprises, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
September 9, 2026 Woodbury Edwina DDirector Received as pay 22 $4.85 $106.7 Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about NUS

What does NU Skin Enterprises, Inc. do?

NU Skin Enterprises, Inc. is registered with the SEC under industry code SIC 5122 (Wholesale-Drugs, Proprietaries & Druggists' Sundries). Its shares trade on NYSE under the ticker NUS.

Is NU Skin Enterprises, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $216.4M on revenue of $1.4B.

How much revenue does NU Skin Enterprises, Inc. make?

Over the twelve months to June 30, 2026 NU Skin Enterprises, Inc. reported revenue of $1.4B. That is 15.4% less than a year earlier.

When did NU Skin Enterprises, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.

Similar companies

Compare NUS with

Compare NUS with any company

Follow NUS

Get an email when NU Skin Enterprises, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow NUS: get an email when it files

Where the numbers come from

Financial figures are the values NU Skin Enterprises, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.